Abdominal aBscess Catheter Sclerotherapy (ABCS)

This is a single center, two arm phase I/II clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. The target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. The primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.

NCT Number	NCT06906029
Lead Sponsor	University of Alabama at Birmingham Collaborators: Argon Medical Devices
Conditions	Abdominal Abscess
Enrollment	60 participants
Start Date	2026-07
Primary Completion	2028-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-30